Tag: curosurf poractant alfa market outlook

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Curosurf (Poractant Alfa) Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?

The historical growth can be attributed to a high occurrence of preterm births, the demonstrated effectiveness in treating respiratory distress syndrome, widespread adoption of neonatal intensive care units, clinical recommendations supporting surfactant therapy, and a reduction in neonatal mortality rates.

Growth during the projected period stems from a global rise in premature births, enhanced NICU facilities, better availability of neonatal care, increased understanding of early respiratory distress syndrome (RDS) intervention, and ongoing clinical verification. Concurrently, major developments anticipated during this timeframe involve an escalation in usage within neonatal intensive care units, a surge in the uptake of synthetic surfactants, heightened attention on managing preterm births, the establishment of uniform RDS treatment guidelines, and the proliferation of hospital-based neonatal treatments.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=27981510&type=smp&name=Curosurf%20%28Poractant%20Alfa%29%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Curosurf (Poractant Alfa) Market Demand Drivers Opening New Revenue Streams

The curosurf (poractant alfa) market is anticipated to expand due to the rising occurrence of respiratory ailments. These conditions encompass common issues impacting the lungs and respiration, including asthma, COPD, and lung cancer, which cause breathing difficulties and diminished lung capacity. The increase in respiratory disorder cases is attributed to heightened air pollution, worsening conditions like asthma, and an aging demographic, which leads to more age-related illnesses such as COPD. Poractant alfa is administered via an endotracheal tube to manage neonatal respiratory distress syndrome, enhancing lung function and aiding breathing in premature babies. As an illustration, the National Library of Medicine, a US-based medical library, stated in December 2023 that the worldwide count of chronic obstructive pulmonary disease (COPD) cases among individuals aged 25 and above is predicted to climb by 23% by 2050, reaching approximately 600 million. Consequently, the growing incidence of respiratory disorders is fueling the expansion of the curosurf (poractant alfa) market. The Curosurf (poractant alfa) market’s expansion is projected to be driven by the increasing occurrence of premature births. Premature births are defined as infants delivered prior to 37 weeks of gestation, contrasting with a typical full-term pregnancy of approximately 40 weeks. The surge in premature births is associated with factors such as advanced maternal age and the greater adoption of assisted reproductive technologies, which frequently result in multiple gestations. Poractant alfa is employed in the management of respiratory distress syndrome in premature infants by decreasing lung surface tension, thereby aiding lung expansion and enhancing oxygen exchange. For example, in July 2025, the Office for National Statistics, a UK-based government department, indicated that England and Wales registered 594,677 live births in 2024, representing an increase of 3,605 (0.6%) from the 591,072 births documented in 2023. Consequently, the rising frequency of premature births is propelling the Curosurf (poractant alfa) market forward.

Curosurf (Poractant Alfa) Market Segment Landscape: Which Areas Lead Development?

The curosurf (poractant alfa) market covered in this report is segmented –

1) By Type: Natural Poractant Alfa, Synthetic Poractant Alfa

2) By Sales Channel: Direct Sales, Distribution Channels, Online Marketplace

3) By Application: Pulmonary Edema, Respiratory Distress Syndrome, Other Respiratory Disorders

4) By End User: Hospitals, Clinics, Ambulance Services

Curosurf (Poractant Alfa) Market Trends Powering Strategic Industry Growth

Leading companies in the curosurf (poractant alfa) market are focused on developing advanced solutions, such as innovative inhaled gene therapy, to address unmet needs in respiratory conditions. Novel inhaled gene therapy is a cutting-edge technique where therapeutic genes are directly administered to the lungs via inhalation, typically through aerosolized particles or nanoparticles. For instance, in November 2024, AlveoGene, a UK-based gene therapy developer, obtained Rare Pediatric Disease Designation (RPDD) from the FDA for AVG-002. This is a novel inhaled gene therapy designed to treat lethal neonatal surfactant protein B (SP-B) deficiency, a severe genetic disorder resulting in respiratory failure in infants. SP-B deficiency, caused by mutations in the SFTPB gene, currently has limited treatment options, primarily relying on lung transplantation. AVG-002 utilizes AlveoGene’s InGenuity platform to deliver a functional SP-B gene directly to the lungs, showing promising results in preclinical studies.

Curosurf (Poractant Alfa) Market Industry Leaders And Competitive Landscape

Major companies operating in the curosurf (poractant alfa) market are Chiesi Farmaceutici S.p.A

View The Full Curosurf (Poractant Alfa) Market Report:

https://thebusinessresearchcompany.com/report/curosurf-poractant-alfa-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Curosurf (Poractant Alfa) Market Top Region By Revenue And Market Share

North America was the largest region in the curosurf (poractant alfa) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the curosurf (poractant alfa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Curosurf (Poractant Alfa) Market Expected To Reach $ Billion By 2030 At % CAGR

The expansion observed in the historical timeframe was driven by a high number of preterm deliveries, the established effectiveness of surfactant therapy for respiratory distress syndrome (RDS), its broad implementation in neonatal intensive care units (NICUs), the backing of clinical protocols for surfactant treatment, and a decline in deaths among newborns.

The expansion observed during the forecast period is largely driven by rising global incidences of preterm births, the broadening of neonatal intensive care unit facilities, enhanced accessibility to neonatal care, growing consciousness regarding early respiratory distress syndrome treatment, and sustained clinical verification. Key developments shaping this future period encompass a greater prevalence of applications in neonatal intensive care, an increasing preference for synthetic surfactant usage, heightened emphasis on managing preterm deliveries, the establishment of consistent protocols for addressing respiratory distress syndrome, and the broader implementation of hospital-centric neonatal treatment approaches.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19893&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

#Curosurf (Poractant Alfa) Market Growth Factors: Which Forces Are Supporting Market Expansion?

The rising occurrence of respiratory disorders is anticipated to drive expansion in the curosurf (poractant alfa) market in the coming period. These disorders, including asthma, COPD, and lung cancer, are common conditions impacting lung function and breathing, leading to difficulties in respiration and diminished pulmonary capacity. Their increasing prevalence stems from factors like worsening air pollution, which triggers asthma exacerbations, and a growing elderly population, which elevates rates of age-linked illnesses such as COPD. Poractant alfa, administered through an endotracheal tube, treats neonatal respiratory distress syndrome by enhancing lung performance and aiding breathing in preterm infants. As an example, the National Library of Medicine, a medical library in the US, projected in December 2023 that global chronic obstructive pulmonary disease (COPD) cases among individuals aged 25 and older would climb by 23% by 2050, hitting nearly 600 million. Consequently, the heightened frequency of respiratory disorders is fueling growth in the curosurf (poractant alfa) market.

Curosurf (Poractant Alfa) Market Driver: Growing Prevalence Of Premature Births Driving The Growth Of The Curosurf (Poractant Alfa) Market

An increasing rate of premature births is set to accelerate the expansion of the Curosurf (poractant alfa) market moving forward. These births happen before 37 weeks of gestation, while a typical full-term pregnancy lasts about 40 weeks. This trend is driven by older maternal ages and greater use of assisted reproductive technologies, which frequently result in multiple pregnancies. Poractant alfa is employed to manage respiratory distress syndrome in premature infants by decreasing lung surface tension, keeping the lungs open, and boosting oxygen exchange. For instance, the Office for National Statistics, a UK government body, reported in July 2025 that live births in England and Wales reached 594,677 in 2024—an uptick of 3,605 (0.6%) from the 591,072 recorded in 2023. Thus, the rising prevalence of premature births is propelling the Curosurf (poractant alfa) market forward.

Curosurf (Poractant Alfa) Market Segment Outlook: Which Categories Are Expanding The Fastest?

The curosurf (poractant alfa) market covered in this report is segmented –

1) By Type: Natural Poractant Alfa, Synthetic Poractant Alfa

2) By Sales Channel: Direct Sales, Distribution Channels, Online Marketplace

3) By Application: Pulmonary Edema, Respiratory Distress Syndrome, Other Respiratory Disorders

4) By End User: Hospitals, Clinics, Ambulance Services

Curosurf (Poractant Alfa) Market Industry Trends: What Changes Are Reshaping Demand?

Major players in the curosurf (poractant alfa) market are concentrating their efforts on creating advanced solutions, including new inhaled gene therapies designed to tackle unmet requirements in respiratory conditions. This innovative strategy, known as novel inhaled gene therapy, represents a state-of-the-art method where therapeutic genes are delivered straight to the lungs through inhalation, often using aerosolized particles or nanoparticles. A concrete example occurred in November 2024, when AlveoGene, a gene therapy firm from the UK, was granted Rare Pediatric Disease Designation (RPDD) by the FDA for AVG-002. This inhaled gene therapy targets lethal neonatal surfactant protein B (SP-B) deficiency, a serious genetic condition causing respiratory failure in newborns. SP-B deficiency results from mutations in the SFTPB gene and, at present, provides limited therapeutic avenues, with lung transplantation being the main option. AVG-002 leverages AlveoGene’s InGenuity platform to deliver a functional SP-B gene directly to lung tissue, and it has demonstrated encouraging outcomes in preclinical tests.

Curosurf (Poractant Alfa) Market Key Companies And Competitive Benchmarking

Major companies operating in the curosurf (poractant alfa) market are Chiesi Farmaceutici S.p.A

Access The Complete Curosurf (Poractant Alfa) Market Report:

https://www.thebusinessresearchcompany.com/report/curosurf-poractant-alfa-global-market-report-?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Curosurf (Poractant Alfa) Market Global Footprint: Which Region Holds Market Leadership?

North America was the largest region in the curosurf (poractant alfa) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the curosurf (poractant alfa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Are The Forecasted Market Size Figures For The Curosurf (Poractant Alfa) Market In 2026 And 2030?

The expansion observed during the historical timeframe is attributable to a significant occurrence of premature births, the demonstrated effectiveness in treating respiratory distress syndrome, the extensive implementation of Neonatal Intensive Care Units, medical directives advocating for surfactant treatment, and a subsequent decline in infant death rates.

The growth in the projected timeframe is primarily driven by factors such as a global rise in premature birth rates, the expansion of neonatal intensive care unit (NICU) infrastructure, improved access to neonatal care, heightened awareness regarding early intervention for Respiratory Distress Syndrome (RDS), and ongoing clinical validation.

Key developments expected during the forecast period include the increasing application in neonatal intensive care settings, the growing acceptance of synthetic surfactants, a stronger focus on managing preterm births, the standardization of RDS treatment protocols, and a broader availability of hospital-based neonatal therapies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19893&type=smp

Which Growth Factors Are Strengthening The Curosurf (Poractant Alfa) Market Landscape?

The curosurf (poractant alfa) market is anticipated to experience growth driven by the rising incidence of respiratory disorders. These common conditions, such as asthma, COPD, and lung cancer, impact the lungs and breathing, leading to compromised lung function and breathing difficulties. The increasing occurrence of respiratory disorders is linked to higher air pollution, which exacerbates issues like asthma, and an aging global population, contributing to a greater prevalence of age-related illnesses such as COPD. Poractant alfa is employed in the treatment of neonatal respiratory distress syndrome to enhance lung function and aid breathing in premature infants, administered via an endotracheal tube. For example, the National Library of Medicine, a US-based medical library, reported in December 2023 that the worldwide count of chronic obstructive pulmonary disease (COPD) cases among individuals aged 25 and older is projected to increase by 23% by 2050, reaching almost 600 million. Thus, the escalating prevalence of respiratory disorders is a significant force behind the expansion of the curosurf (poractant alfa) market.

Curosurf (Poractant Alfa) Market Driver: Growing Prevalence Of Premature Births Driving The Growth Of The Curosurf (Poractant Alfa) Market

How Is The Curosurf (Poractant Alfa) Market Distributed Across Key Segments?

The curosurf (poractant alfa) market covered in this report is segmented –

1) By Type: Natural Poractant Alfa, Synthetic Poractant Alfa

2) By Sales Channel: Direct Sales, Distribution Channels, Online Marketplace

3) By Application: Pulmonary Edema, Respiratory Distress Syndrome, Other Respiratory Disorders

4) By End User: Hospitals, Clinics, Ambulance Services

Which Trends Are Contributing To Changes In The Curosurf (Poractant Alfa) Market?

Leading companies within the curosurf (poractant alfa) market are prioritizing the creation of advanced remedies, such as innovative inhaled gene therapy, to address crucial gaps in managing respiratory conditions. This groundbreaking approach, novel inhaled gene therapy, involves the direct delivery of therapeutic genes into the lungs via inhalation, typically through aerosolized particles or nanoparticles. Illustratively, in November 2024, AlveoGene, a UK-based developer specializing in gene therapy, was granted Rare Pediatric Disease Designation (RPDD) by the FDA for its product AVG-002. AVG-002 represents an innovative inhaled gene therapy aimed at lethal neonatal surfactant protein B (SP-B) deficiency, a severe genetic disorder that leads to respiratory failure in infants. SP-B deficiency, which arises from mutations in the SFTPB gene, currently offers restricted treatment options, primarily dependent on lung transplantation. AVG-002 leverages AlveoGene’s InGenuity platform to introduce a functional SP-B gene directly into the lungs, having demonstrated promising outcomes in preclinical investigations.

Who Are The Businesses Driving Activity In The Curosurf (Poractant Alfa) Market?

Major companies operating in the curosurf (poractant alfa) market are Chiesi Farmaceutici S.p.A

Access The Complete Curosurf (Poractant Alfa) Market Report:

https://www.thebusinessresearchcompany.com/report/curosurf-poractant-alfa-global-market-report-

Which Region Contributes The Most To The Curosurf (Poractant Alfa) Market?

North America was the largest region in the curosurf (poractant alfa) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the curosurf (poractant alfa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Curosurf (Poractant Alfa) Market Expected To Scale Between 2026 And 2030?

Throughout the historical period, growth was driven by a frequent occurrence of premature births, the established effectiveness in treating respiratory distress syndrome (RDS), the extensive implementation of Neonatal Intensive Care Units (NICUs), clinical recommendations endorsing surfactant therapy, and a decrease in neonatal mortality rates.

Growth during the forecast period is projected to be driven by several factors, including the global rise in premature birth rates, the expansion of Neonatal Intensive Care Unit (NICU) infrastructure, improved accessibility to neonatal care, a growing awareness regarding early intervention for Respiratory Distress Syndrome (RDS), and sustained clinical validation.

Significant trends expected within the forecast period include an increasing application in neonatal intensive care settings, the growing adoption of synthetic surfactants, a heightened focus on the management of preterm births, the standardization of RDS treatment protocols, and the broadening provision of hospital-based neonatal therapies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19893&type=smp

What Major Factors Are Driving The Curosurf (Poractant Alfa) Market Forward?

The rising occurrence of respiratory conditions is anticipated to fuel the expansion of the curosurf (poractant alfa) market in the future. These disorders encompass prevalent ailments impacting the lungs and respiration, including asthma, COPD, and lung cancer, resulting in breathing difficulties and diminished pulmonary capacity. The growing frequency of respiratory ailments is attributed to increasing air pollution, which worsens conditions like asthma, alongside an aging demographic that contributes to a greater occurrence of age-related illnesses such as COPD. Poractant alfa serves as a treatment for neonatal respiratory distress syndrome, enhancing lung performance and assisting premature infants with breathing when administered through an endotracheal tube. For example, data from the National Library of Medicine, a US-based medical library, published in December 2023, indicates that worldwide chronic obstructive pulmonary disease (COPD) cases among individuals aged 25 and above are projected to surge by 23% by 2050, reaching almost 600 million. Consequently, the expanding prevalence of respiratory conditions is propelling the market growth for curosurf (poractant alfa).

What Are The Different Segment Types In The Curosurf (Poractant Alfa) Market Segment Breakdown?

The curosurf (poractant alfa) market covered in this report is segmented –

1) By Type: Natural Poractant Alfa, Synthetic Poractant Alfa

2) By Sales Channel: Direct Sales, Distribution Channels, Online Marketplace

3) By Application: Pulmonary Edema, Respiratory Distress Syndrome, Other Respiratory Disorders

4) By End User: Hospitals, Clinics, Ambulance Services

What Trends Are Affecting The Direction Of The Curosurf (Poractant Alfa) Market?

Leading companies in the curosurf (poractant alfa) market are concentrating on developing innovative solutions, such as novel inhaled gene therapy, to meet the unmet needs in various respiratory disorders. This cutting-edge approach, novel inhaled gene therapy, involves delivering therapeutic genes directly to the lungs through inhalation, typically using aerosolized particles or nanoparticles. For instance, in November 2024, AlveoGene, a UK-based gene therapy developer, obtained Rare Pediatric Disease Designation (RPDD) from the FDA for AVG-002, an innovative inhaled gene therapy targeting lethal neonatal surfactant protein B (SP-B) deficiency, a severe genetic condition that leads to respiratory failure in infants. SP-B deficiency, which results from mutations in the SFTPB gene, currently has very few treatment options, primarily depending on lung transplantation. AVG-002 leverages AlveoGene’s InGenuity platform to administer a functional SP-B gene directly to the lungs, exhibiting promising results in preclinical studies.

Who Are The Well-Known Companies In The Curosurf (Poractant Alfa) Market?

Major companies operating in the curosurf (poractant alfa) market are Chiesi Farmaceutici S.p.A

Get The Full Curosurf (Poractant Alfa) Market Report:

https://www.thebusinessresearchcompany.com/report/curosurf-poractant-alfa-global-market-report-

Which Region Accounts For The Largest Portion Of The Curosurf (Poractant Alfa) Market?

North America was the largest region in the curosurf (poractant alfa) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the curosurf (poractant alfa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Curosurf (Poractant Alfa) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/curosurf-poractant-alfa-global-market-report-

Browse Through More Reports Similar to the Global Curosurf (Poractant Alfa) Market 2026, By The Business Research Company

Alfalfa Market Report 2026

https://www.thebusinessresearchcompany.com/report/alfalfa-global-market-report

Compound Camphor Ointment Market Report 2026

https://www.thebusinessresearchcompany.com/report/compound-camphor-ointment-global-market-report

Pharmaceutical Pellets Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-pellets-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Curosurf (Poractant Alfa) Market Projected To Become By 2030 Based On Its 2026 Valuation?

The expansion witnessed in the historical timeframe resulted from a high occurrence of preterm births, the confirmed effectiveness in treating respiratory distress syndrome, the widespread implementation of neonatal intensive care units, clinical directives advocating surfactant therapy, and a decrease in neonatal mortality rates.

The projected growth during the forecast period is due to a worldwide increase in premature birth rates, the expansion of NICU infrastructure, improved access to neonatal care, a rising understanding of early RDS intervention, and continuous clinical validation.

Significant trends expected in the forecast period involve increased application within neonatal intensive care, wider adoption of synthetic surfactants, a stronger focus on preterm birth management, the standardization of RDS treatment protocols, and the expansion of hospital-based neonatal therapies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19893&type=smp

What Primary Drivers Are Shaping The Development Of The Curosurf (Poractant Alfa) Market?

The expanding occurrence of respiratory illnesses is anticipated to fuel the progression of the curosurf (poractant alfa) market in the future. These common conditions, which include asthma, chronic obstructive pulmonary disease (COPD), and lung cancer, impact the lungs and respiration, resulting in breathing difficulties and diminished lung capacity. The increase in these disorders is attributable to rising air pollution, which worsens conditions like asthma, and an aging population, which contributes to a greater frequency of age-related ailments such as COPD. Poractant alfa is employed to manage neonatal respiratory distress syndrome by enhancing lung performance and facilitating breathing for premature infants, delivered through an endotracheal tube. For example, the National Library of Medicine, a US-based medical library, reported in December 2023 that the worldwide number of chronic obstructive pulmonary disease (COPD) cases among individuals aged 25 and above is expected to climb by 23% by 2050, reaching almost 600 million. Consequently, the rising incidence of respiratory disorders is stimulating the expansion of the curosurf (poractant alfa) market.

What Segment Groups Are Identified Within The Curosurf (Poractant Alfa) Market?

The curosurf (poractant alfa) market covered in this report is segmented –

1) By Type: Natural Poractant Alfa, Synthetic Poractant Alfa

2) By Sales Channel: Direct Sales, Distribution Channels, Online Marketplace

3) By Application: Pulmonary Edema, Respiratory Distress Syndrome, Other Respiratory Disorders

4) By End User: Hospitals, Clinics, Ambulance Services

What Trends Are Advancing Progress In The Curosurf (Poractant Alfa) Market?

Leading entities within the curosurf (poractant alfa) market are concentrating on creating advanced solutions, particularly new inhaled gene therapy, to tackle unaddressed requirements for respiratory conditions. This novel inhaled gene therapy represents a state-of-the-art method where therapeutic genetic material is administered straight to the lungs by means of inhalation, usually through aerosolized particles or extremely small particles. As an illustration, during November 2024, AlveoGene, a gene therapy developer situated in the UK, was granted Rare Pediatric Disease Designation (RPDD) by the FDA for its product AVG-002. This product is a pioneering inhaled gene therapy designed to target fatal neonatal surfactant protein B (SP-B) deficiency, which is a critical genetic condition resulting in respiratory failure among infants. SP-B deficiency, originating from mutations within the SFTPB gene, currently possesses restricted treatment alternatives, predominantly involving lung transplantation. AVG-002 leverages AlveoGene’s InGenuity platform to deliver a fully functional SP-B gene directly into the lungs, having demonstrated encouraging outcomes in preclinical investigations.

Which Companies Hold Significant Positions In The Curosurf (Poractant Alfa) Market?

Major companies operating in the curosurf (poractant alfa) market are Chiesi Farmaceutici S.p.A

Read the full curosurf (poractant alfa) market report here:

https://www.thebusinessresearchcompany.com/report/curosurf-poractant-alfa-global-market-report-

How Does The Curosurf (Poractant Alfa) Market Perform Across Major Global Regions?

North America was the largest region in the curosurf (poractant alfa) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the curosurf (poractant alfa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Curosurf (Poractant Alfa) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19893&type=smp

Browse Through More Reports Similar to the Global Curosurf (Poractant Alfa) Market 2026, By The Business Research Company

Alfalfa Market Report 2026

https://www.thebusinessresearchcompany.com/report/alfalfa-global-market-report

Compound Camphor Ointment Market Report 2026

https://www.thebusinessresearchcompany.com/report/compound-camphor-ointment-global-market-report

Pharmaceutical Pellets Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-pellets-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the curosurf (poractant alfa) market from 2026–2035 with trusted insights from The Business Research Company

How much is the Curosurf (Poractant Alfa) Market valued at in 2026, and what valuation is forecast for 2030?

Historically, growth stemmed from the frequent occurrences of premature births, the demonstrated effectiveness in treating respiratory distress syndrome, the widespread implementation of Neonatal Intensive Care Units, clinical recommendations favoring surfactant treatment, and a decrease in infant death rates.

The projected growth in the forecast period is attributable to a global rise in premature birth rates, the expansion of nicu infrastructure, enhanced access to neonatal care, increasing awareness regarding early rds intervention, and continued clinical validation. Prominent trends anticipated during the forecast timeframe include a surge in use within neonatal intensive care, a growing adoption of synthetic surfactants, an increasing focus on preterm birth management, the standardization of rds treatment protocols, and the expansion of hospital-based neonatal therapies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19893&type=smp

What Drivers Are Influencing The Growth Of The Curosurf (Poractant Alfa) Market?

The rise in respiratory conditions is anticipated to fuel the expansion of the curosurf (poractant alfa) market moving forward. These common disorders impact the lungs and breathing, encompassing conditions such as asthma, COPD, and lung cancer, resulting in breathing difficulties and reduced pulmonary function. The increasing incidence of respiratory illnesses is attributed to rising air pollution, which worsens conditions like asthma, and a growing elderly population, contributing to a higher frequency of age-related diseases such as COPD. Poractant alfa is utilized to address neonatal respiratory distress syndrome by enhancing lung function and facilitating respiration in premature infants through an endotracheal tube. For example, in December 2023, the National Library of Medicine, a US-based medical library, stated that the worldwide number of chronic obstructive pulmonary disease (COPD) cases among individuals aged 25 and above is projected to increase by 23% by 2050, reaching nearly 600 million. Consequently, the escalating prevalence of respiratory disorders is propelling the growth of the curosurf (poractant alfa) market. The increasing frequency of premature births is projected to drive the growth of the Curosurf (poractant alfa) market in the coming years. Premature births are defined as babies born prior to 37 weeks of gestation, whereas a full-term pregnancy typically lasts around 40 weeks. The increase in premature births is linked to factors such as older maternal age and a greater reliance on assisted reproductive technologies, which often lead to multiple pregnancies. Poractant alfa is employed to treat respiratory distress syndrome in premature infants by lowering lung surface tension, helping the lungs remain open, and improving oxygen exchange. As an illustration, in July 2025, the Office for National Statistics, a UK-based government department, reported that England and Wales experienced 594,677 live births in 2024, representing an increase of 3,605 (0.6%) from the 591,072 births recorded in 2023. Thus, the growing prevalence of premature births is contributing to the expansion of the Curosurf (poractant alfa) market.

How Is The Curosurf (Poractant Alfa) Market Organized Into Various Segments?

The curosurf (poractant alfa) market covered in this report is segmented –

1) By Type: Natural Poractant Alfa, Synthetic Poractant Alfa

2) By Sales Channel: Direct Sales, Distribution Channels, Online Marketplace

3) By Application: Pulmonary Edema, Respiratory Distress Syndrome, Other Respiratory Disorders

4) By End User: Hospitals, Clinics, Ambulance Services

How Are Emerging Trends Affecting The Progression Of The Curosurf (Poractant Alfa) Market?

Major companies engaged in the curosurf (poractant alfa) market are concentrating their efforts on devising advanced solutions, such as novel inhaled gene therapy, to meet critical unmet needs in various respiratory disorders. This innovative inhaled gene therapy involves a sophisticated technique where therapeutic genes are directly delivered to the lungs via inhalation, typically through the use of aerosolized particles or nanoparticles. For instance, in November 2024, AlveoGene, a UK-based company specializing in gene therapy development, secured Rare Pediatric Disease Designation (RPDD) from the FDA for AVG-002. This particular therapy is a novel inhaled gene therapy aimed at addressing lethal neonatal surfactant protein B (SP-B) deficiency, a severe genetic condition that results in respiratory failure in infants. SP-B deficiency, which stems from mutations in the SFTPB gene, currently has limited therapeutic options, primarily depending on lung transplantation. AVG-002 utilizes AlveoGene’s InGenuity platform to introduce a functional SP-B gene directly into the lungs, showing promising early results in preclinical studies.

Who Are The Core Companies Influencing Trends In The Curosurf (Poractant Alfa) Market?

Major companies operating in the curosurf (poractant alfa) market are Chiesi Farmaceutici S.p.A

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/curosurf-poractant-alfa-global-market-report-

Which Regions Are Projected To Dominate The Curosurf (Poractant Alfa) Market In The Coming Years?

North America was the largest region in the curosurf (poractant alfa) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the curosurf (poractant alfa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Curosurf (Poractant Alfa) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19893&type=smp

Browse Through More Reports Similar to the Global Curosurf (Poractant Alfa) Market 2026, By The Business Research Company

Alfalfa Market Report 2026

https://www.thebusinessresearchcompany.com/report/alfalfa-global-market-report

Compound Camphor Ointment Market Report 2026

https://www.thebusinessresearchcompany.com/report/compound-camphor-ointment-global-market-report

Pharmaceutical Pellets Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-pellets-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Market Size of the Curosurf (Poractant Alfa) Market In 2029?

In recent years, the market size for curosurf (poractant alfa) has registered an XX% growth (HCAGR). It’s estimated to expand from $XX million in 2024 to $XX million by 2025, reflecting a compound annual growth rate (CAGR) of XX%. The historical period’s expansion is credited to the heightened demand for sophisticated medical solutions, synthetic surfactants in cleanliness products, enhanced consciousness about healthcare and improved healthcare accessibility, a rising preference for uncomplicated cleaning methods promoting synthetic surfactant sales, and an overall increase in healthcare awareness.

What Growth Rate Is Forecasted for the Curosurf (Poractant Alfa) Market by 2029?

The market of curosurf (poractant alfa) is predicted to experience a growth rate of XX (FCAGR) in the coming years, reaching $XX million by 2029 with a compounded annual growth rate (CAGR) of XX%. This growth during the forecasted period can be associated with the increased levels of premature births, an increase in the application of synthetic surfactants in agrochemicals, a sharp rise in chronic respiratory disease cases, more spending on healthcare, and a growing inclination towards respiratory infection treatment. Key trends anticipated during this period are the adoption of microdosing methodologies, incorporation of surfactant therapy, embracement of biologic and immunomodulatory therapies, movement towards environmentally friendly and sustainable surfactants, and attention to neonatal and pediatric care.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19893&type=smp

Which Key Companies Are Shaping the Future of the Curosurf (Poractant Alfa) Market?

Major companies operating in the curosurf (poractant alfa) market include Chiesi Farmaceutici S.p.A

Which Factors Are Driving Demand in the Curosurf (Poractant Alfa) Industry?

The surge in respiratory disorders is anticipated to fuel the advancement of the curosurf (poractant alfa) market in the future. The term “respiratory disorders” encompasses common conditions that impact the lungs and affect breathing; these include ailments such as asthma, COPD, and lung cancer, which tend to lead to hindered breathing and diminished lung functionality. The escalating instances of respiratory disorders can be attributed to increasing air pollution, which often worsens conditions like asthma, and an aging population, which tends to have a higher occurrence of age-specific diseases, including COPD. Poractant alfa is utilized as a treatment option for neonatal respiratory distress syndrome; it enhances lung function and simplifies the breathing process in premature babies via administration through an endotracheal tube. For example, in Australia, according to the National Asthma Council—an Australian not-for-profit organization—in November 2023, the country numbered 467 asthma-related fatalities in 2022, with 299 females and 168 males accounted for; these figures indicate a rise from the 355 deaths documented in 2021. As such, the escalating instances of respiratory disorders are propelling the growth of the curosurf (poractant alfa) market. The increase in premature births is predicted to give rise to the expansion of the Curosurf (poractant alfa) market in the coming years. Premature births refer to babies born prior to 37 weeks of gestation; for perspective, a regular term pregnancy is usually about 40 weeks. The noted increase in premature births can be associated with older maternal age and the augmented use of assisted reproductive technologies, which often result in multiple pregnancies. Poractant alfa is leveraged as a treatment for infants born prematurely with respiratory distress syndrome—it minimizes lung surface tension, helps in keeping the lungs open, and boosts oxygen exchange capabilities. For example, according to the Office for National Statistics—a government department based in the UK—in May 2024, England and Wales saw a premature live birth rate of 7.9% in 2022, a rise from the 7.5% noted in 2021. Therefore, the growing prevalence of premature births is causing a surge in the growth of the Curosurf (poractant alfa) market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=19893&type=smp

How Is the Curosurf (Poractant Alfa) Market Segmented by Several Divisions?

The curosurf (poractant alfa)market covered in this report is segmented –

1) By Type: Natural Poractant Alfa; Synthetic Poractant Alfa

2) By Sales Channel: Direct Sales; Distribution Channels; Online Marketplace

3) By Application: Pulmonary Edema; Respiratory Distress Syndrome; Other Respiratory Disorders

4) By End User: Hospitals; Clinics; Ambulance Services

What are the Emerging Market Trends Driving the Growth of the Curosurf (Poractant Alfa) Industry?

A significant development in the curosurf (poractant alfa) market is the concentration on creating innovative treatments, particularly a new inhaled gene therapy to cater to unaddressed needs in respiratory ailments. This advanced therapy involves the direct delivery of therapeutic genes to the lungs through inhalation, typically via aerosolized particles or nanoparticles. As an example, AlveoGene, a gene therapy developer based in the UK, was granted the Rare Pediatric Disease Designation (RPDD) by the FDA in November 2024 for AVG-002. This new inhaled gene therapy targets the lethal neonatal surfactant protein B (SP-B) deficiency, a severe genetic disorder causing respiratory failure in newborns. Treatment options for SP-B deficiency, which arises from mutations in the SFTPB gene, are currently limited and mostly involve lung transplantation. AVG-002 employs AlveoGene’s InGenuity platform for direct delivery of a functional SP-B gene to the lungs which has demonstrated promising results in early laboratory studies.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/curosurf-poractant-alfa-global-market-report-

Which Regions Are Driving Growth in the Curosurf (Poractant Alfa) Market?

North America was the largest region in the curosurf (poractant alfa) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the curosurf (poractant alfa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19893

This Report Delivers Insight On:

1. How big is the curosurf (poractant alfa) market, and how is it changing globally?

2. Who are the major companies in the curosurf (poractant alfa) market, and how are they performing?

3. What are the key opportunities and risks in the curosurf (poractant alfa) market right now?

4. Which products or customer segments are growing the most in the curosurf (poractant alfa) market?

5. What factors are helping or slowing down the growth of the curosurf (poractant alfa) market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the curosurf (poractant alfa) global market report 2025 industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Are the Projected Market Size and Growth Rates for the Curosurf (Poractant Alfa) Market From 2025 To 2029?

In the recent past, there has been a noticeable expansion of the poractant alfa, or curosurf, market in the view of XX% HCAGR. The projected increase shows a progression from $XX million in 2024 to $XX million in 2025, exemplifying a promising compound annual growth rate (CAGR) of XX%. Several factors account for this growth during the historic period, such as the escalated demand for superior medical solutions, interest towards synthetic surfactants employed in hygiene products, greater awareness about healthcare paired with improved healthcare accessibility, the leaning towards simple cleanliness that escalates synthetic surfactant sales, and the overall increase in healthcare awareness.

The market for curosurf (poractant alfa) is projected to experience an expansion with an approximated compound annual growth rate (CAGR) of XX% in the upcoming years, reaching a valuation of $XX million in 2029. The progression in the analysis period is primarily due to the escalating rates of preterm births, higher adoption of synthetic surfactants in the agrochemical industry, increasing cases of chronic respiratory diseases, more healthcare spending, and a growing preference for treating respiratory infections. Key trends expected during the forecast period include the embrace of microdosing methods, integrating surfactant therapy, the usage of biologic and immunomodulatory therapies, a shift towards eco-friendly and sustainable surfactants, along with emphasis on neonatal and pediatric care.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19893&type=smp

What External and Internal Drivers Are Contributing to the Growth of the Curosurf (Poractant Alfa) Market?

The escalating instances of respiratory diseases are projected to fuel the curosurf (poractant alfa) market’s expansion. Respiratory diseases encompass common ailments that impact the lungs and impede breathing such as asthma, COPD, and lung cancer, causing breathing difficulties and decreased lung efficiency. The growing occurrence of respiratory ailments is propelled by the increase in air pollution, which worsens conditions like asthma, and the aging populace, leading to the higher occurrence of age-related illnesses like COPD. Poractant alfa serves as a treatment for neonatal respiratory distress syndrome by enhancing lung performance and aiding breathing in premature infants through the endotracheal tube administration. For example, the National Asthma Council, an Australian non-profit organization stated in November 2023 that in Australia, there were 467 recorded deaths from asthma in 2022, which comprised 299 females and 168 males, an increase from the 355 deaths observed in 2021. Thus, the escalating prevalence of respiratory diseases is propelling the curosurf (poractant alfa) market’s expansion. There is an upward trend in premature births propelling the advancement of the Curosurf (poractant alfa) market. Premature births are instances where babies are born prior to 37 weeks of pregnancy, as a full-term pregnancy generally lasts about 40 weeks. The increased incidents of premature births are associated with older maternal age and the increased usage of assisted reproductive technologies, often resulting in multiple pregnancies. Poractant alfa is utilized to treat respiratory distress syndrome in premature infants, lowering lung surface tension, ensuring the lungs remain open, and enhancing oxygen exchange. For example, in May 2024, according to the Office for National Statistics, a UK governmental department, the rate of premature live births in England and Wales in 2022 was recorded at 7.9%, a rise from the 7.5% in 2021. Therefore, the rising occurrence of premature births is propelling the Curosurf (poractant alfa) market’s growth.

What Segment Types Define the Curosurf (Poractant Alfa) Market Structure?

The curosurf (poractant alfa)market covered in this report is segmented –

1) By Type: Natural Poractant Alfa; Synthetic Poractant Alfa

2) By Sales Channel: Direct Sales; Distribution Channels; Online Marketplace

3) By Application: Pulmonary Edema; Respiratory Distress Syndrome; Other Respiratory Disorders

4) By End User: Hospitals; Clinics; Ambulance Services

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=19893&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Curosurf (Poractant Alfa) Market?

North America was the largest region in the curosurf (poractant alfa) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the curosurf (poractant alfa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Curosurf (Poractant Alfa) Market?

The prevailing trend within the Curosurf (poractant alfa) market revolves around the creation of innovative solutions such as unique inhaled gene therapies to cater to the unresolved necessities in respiratory disorders. This extraordinarily advanced inhaled gene therapy refers to the procedure in which the therapeutic genes are administered straight to the lungs through inhalation, typically via aerosolized particles or nanoparticles. A prime exemplification of this occurred in November 2024 when AlveoGene, a pioneering gene therapy developer from the UK, earned the Rare Pediatric Disease Designation (RPDD) from the FDA for AVG-002. This unique inhaled gene therapy aims to address the fatal neonatal surfactant protein B (SP-B) deficiency, a debilitating genetic abnormalities causing respiratory failure in young infants. The condition, caused by alterations in the SFTPB gene, presently has scarce treatment alternatives, largely dependent on lung transplantation. AVG-002, aided by AlveoGene’s InGenuity platform, delivers a functional SP-B gene straight to the lungs, presenting promising outcomes in preliminary studies.

View the full report here:

https://www.thebusinessresearchcompany.com/report/curosurf-poractant-alfa-global-market-report-

What Is the Definition of the Curosurf (Poractant Alfa) Market?

Curosurf (poractant alfa) refers to a synthetic pulmonary surfactant used primarily for the treatment and prevention of respiratory distress syndrome (RDS) in preterm neonates. It is a synthetic version of a natural substance called pulmonary surfactant, which is produced in the lungs to help reduce surface tension and prevent the collapse of the alveoli (small air sacs) in the lungs.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19893

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What External and Internal Drivers Are Contributing to the Growth of theCurosurf (Poractant Alfa) Market?

The surge in respiratory disorder cases is predicted to boost the growth of the curosurf (poractant alfa) market. Respiratory disorders, encompassing conditions like asthma, COPD, and lung cancer, impact breathability and can deteriorate lung function. Factors such as escalating air pollution, which worsens diseases like asthma, and an aging populace, contributing to the rise of age-specific diseases like COPD, increase the prevalence of these disorders. Poractant alfa aids in treating neonatal respiratory distress syndrome by enhancing lung function and easing the respiratory process in premature babies via an endotracheal tube. To illustrate, the National Asthma Council highlighted in November 2023 that in Australia, the number of asthma-related fatalities in 2022 was seen at 467, consisting of 299 females and 168 males. This total marks an escalation from the 355 deaths previously noted in 2021. As such, the surge in respiratory disorder cases is giving a boost to the curosurf (poractant alfa) market. A rise in premature births is also anticipated to steer the growth of the Curosurf (poractant alfa) market. Premature births include babies born before the full 37-week gestation period. This increase in premature birth rates has been correlated to higher maternal ages and a rise in assisted reproductive technologies usage, frequently resulting in multiple pregnancies. Poractant alfa serves to help premature babies with respiratory distress syndrome by lowering lung surface tension, assisting in keeping the lungs open, and enhancing oxygen exchange. For instance, the Office for National Statistics revealed in May 2024 that the premature live birth rate in England and Wales came out to 7.9% in 2022, marking an increase from the 7.5% in 2021. As such, the rise in premature births is driving the Curosurf (poractant alfa) market’s expansion.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19893&type=smp

What is the Predicted Annual Growth Rate of theCurosurf (Poractant Alfa) Market Impact Industry Trends by 2034?

The Curosurf (poractant alfa) market has maintained a steady HCAGR recently. It is projected to grow from $XX million in 2024 to $XX million in 2025, at a CAGR of XX%. Historic market growth was supported by demand for advanced medical and synthetic surfactants, increased hygiene product use, healthcare awareness, and improved access.

The curosurf (poractant alfa) market will grow to $XX million in 2029 at a CAGR of XX%. Market growth comes from rising premature birth rates, synthetic surfactant use, respiratory disease prevalence, increased healthcare spending, and infection treatment preference. Trends include microdosing, surfactant therapy integration, biologic adoption, green surfactants, and neonatal care focus.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19893

Which Upcoming Market Trends and Innovations Are Set to Influence theCurosurf (Poractant Alfa) Market’s Path Forward?

The primary trend in the curosurf (poractant alfa) market is centered around the development of novel and inventive solutions, particularly innovative inhaled gene therapy, to cater to the unfulfilled needs in dealing with respiratory conditions. This new therapy method essentially puts therapeutic genes directly into the lungs through inhalation, mostly using aerosolized particles or nanoparticles for delivery. A notable example of this is when AlveoGene, a gene therapy developer based in the UK, got Rare Pediatric Disease Designation (RPDD) from the FDA in November 2024 for their novel inhaled gene therapy AVG-002. AVG-002 is designed to engage with the fatal neonatal surfactant protein B (SP-B) deficiency – a serious genetic disorder causing respiratory failure in infants. Currently, treatments for SP-B deficiency, caused by SFTPB gene mutations, are limited and generally involve lung transplantation. However, AVG-002, leveraging AlveoGene’s InGenuity platform, delivers a working SP-B gene straight to the lungs and has shown encouraging results in preclinical research.

Who Are the Dominant Market Players Pushing the Boundaries of theCurosurf (Poractant Alfa) Market?

Major companies operating in the curosurf (poractant alfa) market include Chiesi Farmaceutici S.p.A

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/curosurf-poractant-alfa-global-market-report-

What Are the Core Segments of the Curosurf (Poractant Alfa) Market, and How Do They Contribute to Growth?

The curosurf (poractant alfa)market covered in this report is segmented –

1) By Type: Natural Poractant Alfa; Synthetic Poractant Alfa

2) By Sales Channel: Direct Sales; Distribution Channels; Online Marketplace

3) By Application: Pulmonary Edema; Respiratory Distress Syndrome; Other Respiratory Disorders

4) By End User: Hospitals; Clinics; Ambulance Services

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=19893&type=smp

What Regions Are Dominating the Curosurf (Poractant Alfa) Market Growth?

North America was the largest region in the curosurf (poractant alfa) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the curosurf (poractant alfa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Curosurf (Poractant Alfa) Market 2025, By The Business Research Company:

Anti-Vascular Endothelial Growth Factor Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-vascular-endothelial-growth-factor-therapeutics-global-market-report

Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/vascular-endothelial-growth-factor-inhibitors-global-market-report

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the curosurf (poractant alfa) market grown over the years?

The market size for curosurf (poractant alfa) has seen a HCAGR of XX in the past few years. The projection is that it will escalate from an impressive $XX million in 2024 to a promising $XX million in 2025, boasting a compound annual growth rate (CAGR) of XX%. This substantial growth over the historical period is a result of a soaring demand for cutting-edge medical solutions, an upturn in the requirement for synthetic surfactants used in sanitary products, heightened awareness of and access to healthcare, growing preference for easy cleanliness consequently driving sales of synthetic surfactant, and an overall increase in health consciousness.

What Is the forecasted market size and growth rate for the curosurf (poractant alfa) market?

The market size of curosurf (poractant alfa) is projected to grow at a compound annual growth rate (CAGR) of XX% over the next few years, increasing to $XX million by 2029. This growth in the forecast period is ascribed to the increasing incidence of premature births, the widening application of synthetic surfactants in agrochemicals, the escalating occurrence of chronic respiratory diseases, larger healthcare spending, and a growing inclination towards respiratory infection treatments. The major trends emerging in this forecast period encompass the initiation of microdosing strategies, the incorporation of surfactant therapy, the rise in adoption of biologic and immunomodulatory therapies, a drift towards sustainable and green surfactants, and an emphasis on neonatal and pediatric care.

Get your curosurf (poractant alfa) market report here!

https://www.thebusinessresearchcompany.com/report/curosurf-poractant-alfa-global-market-report-

What are the major factors driving growth in the curosurf (poractant alfa) market?

The anticipated surge in the Curosurf (poractant alfa) market is linked to the rising frequency of respiratory disorders. These common complications encompass conditions like COPD, asthma, and lung cancer, which hamper breathing and impair lung functions. The escalating cases of respiratory disorders are attributable to rampant air pollution aggravating problems like asthma and an increasingly aging population prone to age-related ailments like COPD. Poractant alfa is commonly used to alleviate symptoms of neonatal respiratory distress syndrome by enhancing lung function and aiding breathing in premature infants via an endotracheal tube. As per the National Asthma Council, an Australian non-profit entity, in November 2023, in Australia, 467 deaths related to asthma were recorded in 2022, including 299 females and 168 males. This data indicates an upward shift from 355 fatalities documented in 2021. Hence, the escalating rates of respiratory disorders are fuelling the expansion of the Curosurf (poractant alfa) market. The soaring cases of premature births are likely to steer the growth of the Curosurf (poractant alfa) market. Premature births define the birth of infants prior to completion of 37 weeks of gestation in a typically 40-week full-term pregnancy. The uptick in premature births is related to an increase in the maternal age and amplified usage of assisted reproductive technologies, resulting often in multiple pregnancies. Poractant alfa is utilized to manage premature infants battling respiratory distress syndrome by minimizing lung surface tension, facilitating the lungs to remain open and enhancing oxygen exchange. As per data by the Office for National Statistics, a government department in the UK, in May 2024, in 2022, the premature live birth rate in England and Wales witnessed a rise to 7.9%, from 7.5% in 2021. This thereby implies that the rising occurrence of premature births is propelling the surge in Curosurf (poractant alfa) market.

What key areas define the segmentation of the global curosurf (poractant alfa) Market?

The curosurf (poractant alfa)market covered in this report is segmented –

1) By Type: Natural Poractant Alfa; Synthetic Poractant Alfa

2) By Sales Channel: Direct Sales; Distribution Channels; Online Marketplace

3) By Application: Pulmonary Edema; Respiratory Distress Syndrome; Other Respiratory Disorders

4) By End User: Hospitals; Clinics; Ambulance Services

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19893&type=smp

What are the top market players propelling the growth of the curosurf (poractant alfa) industry?

Major companies operating in the curosurf (poractant alfa) market include Chiesi Farmaceutici S.p.A

What are the key trends shaping the future of the curosurf (poractant alfa) market?

The curosurf (poractant alfa) market’s principal trend is gearing towards the creation of innovative solutions such as groundbreaking inhaled gene therapy addressing unserved demands in respiratory diseases. This sophisticated strategy refers to the application of therapeutic genes directly to the lungs via inhalation, typically done through aerosolized particles or nanoparticles. For instance, in November 2024, AlveoGene, a UK based firm developing gene therapies, obtained Rare Pediatric Disease Designation (RPDD) from the FDA for AVG-002. This is an original inhaled gene therapy targeting the deadly neonatal surfactant protein B (SP-B) deficiency – a severe genetic disorder leading to respiratory collapse in newborns. Currently, solutions for SP-B deficiency caused by mutations in the SFTPB gene, are scarce with lung transplantation being the principal treatment. AVG-002 uses AlveoGene’s InGenuity platform to deliver a working SP-B gene directly to the lungs, showing promising potential in preclinical trials.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19893

What regions are dominating the curosurf (poractant alfa) market growth?

North America was the largest region in the curosurf (poractant alfa) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the curosurf (poractant alfa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Anti-Vascular Endothelial Growth Factor Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-vascular-endothelial-growth-factor-therapeutics-global-market-report

Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/vascular-endothelial-growth-factor-inhibitors-global-market-report

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: